Bahlas S, Ramos-Remus C, Davis P
Rheumatic Disease Unit, University of Alberta, Edmonton, Canada.
J Rheumatol. 1998 Jan;25(1):99-104.
To assess the clinical outcome of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
All charts of consecutive patients with a diagnosis of PMR and/or GCA attending a tertiary referral center from June 1989 to February 1996 were reviewed following a predetermined protocol. Subsequently, the majority of patients (90%) were assessed clinically or by telephone interview. Registered variables included demographic data, disease characteristics, prednisone dosage and duration, comorbidities, and clinical outcomes.
There were 149 patients (133 with PMR alone, 7 with GCA alone, 9 with both); 94 (63%) were females; the mean age was 68 +/- 9 years, and the mean disease duration from the first symptom to the rheumatology consultation was 13 +/- 12 weeks (1-99). Typical clinical features of PMR were present in patients with PMR. Synovitis was observed in 26 patients. The presenting symptoms for GCA were typical features in 13 patients and blindness in 3 (2%) patients. Mean followup was 3.7 +/- 2 years. Comorbid conditions were present in 71 patients: 12 patients had hypertension, 13 had fractures, 8 diabetes, 29 cataract, 8 major infection, and 37 had other complications. Cancer was diagnosed in 4 patients and 6 patients had died. Prednisone was prescribed in 148 patients (mean dose 23 +/- 14 mg) for a mean time of 28 +/- 29 mo. Nonsteroidal antiinflammatory drugs were prescribed in 51 (34%) patients and methotrexate in 2. Disease remission was achieved in 81 (54%) patients (72 remissions, 9 presumed remissions) in whom steroid therapy had been stopped. Another 54 (36%) patients were still taking prednisone at the time of the interview, all were in clinical remission. Seventeen patients developed rheumatoid arthritis subsequent to the diagnosis of PMR.
PMR and GCA should not necessarily be considered diseases with favorable outcome. In many of our patients, steroids were required for a prolonged period. Some patients developed significant complications attributable to steroid therapy. A significant number of patients progressed to rheumatoid arthritis.
评估风湿性多肌痛(PMR)和巨细胞动脉炎(GCA)患者的临床结局。
按照预定方案,对1989年6月至1996年2月在一家三级转诊中心就诊的连续诊断为PMR和/或GCA的所有患者病历进行回顾。随后,对大多数患者(90%)进行了临床评估或电话访谈。记录的变量包括人口统计学数据、疾病特征、泼尼松剂量和疗程、合并症以及临床结局。
共有149例患者(133例仅患PMR,7例仅患GCA,9例两者均患);94例(63%)为女性;平均年龄为68±9岁,从首次出现症状到风湿科就诊的平均病程为13±12周(1 - 99周)。PMR患者具有PMR的典型临床特征。26例患者出现滑膜炎。GCA的首发症状在13例患者中为典型特征,3例(2%)患者出现失明。平均随访时间为3.7±2年。71例患者存在合并症:12例患者患有高血压,13例有骨折,8例有糖尿病,29例有白内障,8例有严重感染,37例有其他并发症。4例患者被诊断出患有癌症,6例患者死亡。148例患者使用了泼尼松(平均剂量23±14mg),平均使用时间为28±29个月。51例(34%)患者使用了非甾体抗炎药,2例患者使用了甲氨蝶呤。81例(54%)患者实现了疾病缓解(72例完全缓解,9例推测为缓解),这些患者已停用类固醇治疗。在访谈时,另有54例(36%)患者仍在服用泼尼松,所有患者均处于临床缓解状态。17例患者在诊断为PMR后发展为类风湿关节炎。
PMR和GCA不一定应被视为预后良好的疾病。在我们的许多患者中,需要长期使用类固醇。一些患者出现了归因于类固醇治疗的严重并发症。相当数量的患者进展为类风湿关节炎。